KR100927970B1 - Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition - Google Patents
Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition Download PDFInfo
- Publication number
- KR100927970B1 KR100927970B1 KR1020070110408A KR20070110408A KR100927970B1 KR 100927970 B1 KR100927970 B1 KR 100927970B1 KR 1020070110408 A KR1020070110408 A KR 1020070110408A KR 20070110408 A KR20070110408 A KR 20070110408A KR 100927970 B1 KR100927970 B1 KR 100927970B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- acne
- twill
- cosmetic composition
- sebum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 80
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 64
- 206010000496 acne Diseases 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 210000002374 sebum Anatomy 0.000 title claims abstract description 54
- 239000002537 cosmetic Substances 0.000 title claims abstract description 43
- 230000028327 secretion Effects 0.000 title claims abstract description 34
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- -1 acryl Chemical group 0.000 title description 14
- 238000009472 formulation Methods 0.000 claims description 28
- 239000006210 lotion Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 241000207961 Sesamum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 230000002401 inhibitory effect Effects 0.000 abstract description 26
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 22
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 6
- 229960003473 androstanolone Drugs 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 229920000742 Cotton Polymers 0.000 description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 239000006071 cream Substances 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 238000004040 coloring Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 235000011869 dried fruits Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 229940079894 benzophenone-9 Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010049141 Acne fulminans Diseases 0.000 description 1
- 206010000507 Acne infantile Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027026 Mechanical acne Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001428357 Trapa japonica Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940002385 chelidonium majus extract Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- ULULAZKOCFNOIM-UHFFFAOYSA-N hexyl 4-hydroxybenzoate Chemical compound CCCCCCOC(=O)C1=CC=C(O)C=C1 ULULAZKOCFNOIM-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 능실 추출물을 유효성분으로 함유하는 5α-리덕테이즈의 활성 억제용 조성물에 관한 것이다. 또한, 본 발명은 5α-리덕테이즈의 활성을 억제함으로써 다이하이드로테스토스테론의 생성을 억제하여 화장료 조성물의 유효성분으로 사용했을 때 피지의 과잉 분비 억제 효과 및 여드름 개선 효과가 우수하다. 따라서, 본 발명에 따른 능실 추출물은 피부에 안전한 농도에서 여드름 완화 효과 및 피지 분비 억제 효과가 있으므로 피지 분비 억제 또는 여드름 완화 화장료에 유효농도로 사용될 수 있다. The present invention relates to a composition for inhibiting activity of 5α-reductase containing a twill extract as an active ingredient. In addition, the present invention suppresses the production of dihydrotestosterone by inhibiting the activity of 5α-reductase, and when used as an active ingredient of the cosmetic composition, it is excellent in the effect of inhibiting excessive secretion of sebum and improving acne. Therefore, the twill extract according to the present invention can be used at an effective concentration in sebum secretion or acne relief cosmetics because it has an acne relief effect and sebum secretion inhibitory effect at a safe concentration on the skin.
능실 추출물, 5α-리덕테이즈, 여드름, 피지 분비 억제, 화장료 조성물 Twill Extract, 5α-Reductase, Acne, Sebum Inhibition, Cosmetic Composition
Description
본 발명은 능실 추출물을 유효성분으로 함유하는 5α-리덕테이즈 활성 억제용 조성물에 관한 것이다. The present invention relates to a composition for inhibiting 5α-reductase activity, containing a twill extract as an active ingredient.
또한 본 발명은 5α-리덕테이즈 억제능력이 있는 능실 추출물을 함유하여 피지 분비 억제 및 여드름 완화용 화장료 조성물에 관한 것이다.In addition, the present invention relates to a cosmetic composition for inhibiting sebum secretion and acne alleviation by containing a twill extract having a 5α-reductase inhibitory ability.
5α-리덕테이즈(5-reductase)는 피지선, 모낭, 전립선, 부고환 등의 남성 호르몬 반응성 조직에 존재하며, 남성 호르몬들 중 하나인 테스토스테론(Testosterone)을 다이하이드로테스토스테론(Dihydrotestosterone:DHT)으로 환원시키는데 관여하는 효소로서 그 전환에는 엔에이디피에이치(NADPH)를 필요로 한다. 남성 성충동, 골격근 증가, 남성외부생식기, 음낭 성장, 정자 형성 등에는 테스토스테론이 관여하고, 여드름, 피지, 전립선비대증 등에는 다이하이드로테스토스테론이 해당 조직에서 관여한다.(Diane et al; JID 775-778, 1995. Bruchovsky, N et al; JBC 243,2112~2121, 1968). 따라서, 5α-리덕테이즈 효소의 억제제를 사용하여 여드름 치료제 및 피지분비 억제제를 개발하려는 연구들이 활발히 진행되고 있다. 5-α-reductase is present in testosterone-reactive tissues such as sebaceous glands, hair follicles, prostate, and epididymis, reducing testosterone, one of the testosterones, to dihydrotestosterone (DHT). As an enzyme involved, its conversion requires NDPH (NADPH). Testosterone is involved in male impulses, skeletal muscle growth, male external genitalia, scrotum growth, and spermatogenesis, and dihydrotestosterone is involved in acne, sebum, and prostatic hyperplasia (Diane et al; JID 775-778, 1995. Bruchovsky, N et al; JBC 243, 2112-2121, 1968). Therefore, studies are actively underway to develop acne therapy and sebum secretion inhibitors using inhibitors of 5α-reductase enzyme.
일반적으로 두피, 얼굴을 포함한 피부에서 피지는, 피부의 보습유지나 미생물의 침입을 막는 역할을 담당하고 있지만, 사춘기 이후에는 여드름을 유발 시킨다. 특히, 20대 이후의 여성의 경우에는 피지의 과잉 분비로 인해 피부 번들거림, 화장의 들뜸 및 모공이 넓어지는 등 미용 면에서 많은 문제를 유발시킨다. 피지 과잉이 일어나는 데는 여러가지 원인이 관여하고 있는데, 그 중에서도 가장 중요한 것은 피지선의 활성에 있어 피지 분비를 촉진하는데 관여하는 호르몬의 하나인 다이하이드로테스토스테론의 양에 의해서 피지선의 세포가 활성화되어 피지 과분비가 일어난다고 알려져 있다. In general, sebum in the skin, including the scalp and face is responsible for maintaining the skin's moisturizing and microorganisms invasion, but after puberty causes acne. In particular, women in their 20s and later causes a lot of problems in terms of beauty, such as skin swelling, lifting of makeup and widening pores due to excessive secretion of sebum. Sebaceous excess is caused by various causes, the most important of which is the sebum gland is activated by the amount of dihydrotestosterone, one of the hormones involved in promoting sebum secretion, sebum hypersecretion It is known.
여드름은 하나의 원인이 아니라 여러 가지 원인이 복합적으로 관여하는데, 사춘기의 남성 호르몬 기능 항진으로 피지선의 분비가 왕성해지고 모낭의 상피세포가 이상을 이르켜 모낭이 막히고 이로인해 여드름의 기본 병변인 면포가 형성된다. 모낭 내에 상주하는 균은 자유-지방산(free fatty acid)을 생성하여 모낭을 자극하여 염증을 유발한다. 이러한 여드름으로의 진행은 피지 과분비로인해 더욱 악화된다.Acne is not a single cause, but a combination of various causes. Hyperplasia of the sebaceous glands is active due to hyperactivity of pubertal hormones, epithelial cells of hair follicles are blocked, and clogged hair follicles. Is formed. Bacteria that reside in hair follicles produce free fatty acids that stimulate hair follicles to cause inflammation. This progression to acne is exacerbated by sebum oversecretion.
이러한 남성 호르몬 억제로 인한 여드름 치료를 위해, 종래에는 에스트로겐 등의 여성 호르몬을 사용하거나 5α-리덕테이즈 억제제를 이용해왔다. 그러나 이러한 여성 호르몬제들은 여드름 치료 효과 외에, 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등이 보고 되고 있어, 현재는 사용을 중단하거나 매우 극미량을 사 용하고 있는 실정이다. 한편, 피지 과분비를 억제하는 여드름 치료제로 5α-리덕테이즈의 억제제인 아젤레익산(azelaic acid)을 15~20 가량 함유한 제제로 시판되고 있다. For the treatment of acne due to such testosterone suppression, female hormones such as estrogen have been conventionally used or 5α-reductase inhibitors have been used. However, these female hormonal agents, in addition to the treatment of acne, skin inflammation, side effects caused by the administration of hormones have been reported, the current situation is discontinued or used in very small amounts. On the other hand, it is commercially available as a preparation containing 15 to 20 azeleic acid (azelaic acid) inhibitor of 5α-reductase as an acne treatment agent that inhibits sebum oversecretion.
한편, 화장품 분야에서도 피지의 과분비는 화장품의 들뜸이나 모공이 넓어지게 되는 요인으로서 중요한 관심의 대상임에도 불구하고 그 연구는 미미한 실정이다. 현재 피지 억제 화장품은, 일시적으로 피지를 흡착시키는 다공성 파우더를 사용하거나, 기존에 피지를 억제한다고 알려진 생약 추출물인 아이비 추출물 등을 화장품 원료로 사용하고 있으나 그 효과는 미미하다.On the other hand, even in the cosmetic field, sebum oversecretion is a factor of interest as a factor causing the lifting of the cosmetics and widening of the pores, but the study is insignificant. Currently, sebum inhibiting cosmetics use a porous powder that temporarily adsorbs sebum or ivy extract, which is a herbal extract known to inhibit sebum, as a cosmetic raw material, but its effect is insignificant.
이에, 본 발명자들은 피지 분비, 여드름 생성 등을 유발한다고 알려져 있는 다이하이드로테스토스테론의 양을 조절하고자, 다이하이드로테스토스테론을 촉매하는 효소인 5α-리덕테이즈의 활성을 억제하는 천연 추출물을 찾고자 노력한 결과, 여러 천연물들 중에서 능실이 5α-리덕테이즈의 저해 효과, 피지분비 효과 및 여드름 완화 효과가 특히 우수한 것을 발견함으로써 본 발명을 완성하였다.Accordingly, the present inventors have tried to find a natural extract that inhibits the activity of 5α-reductase, an enzyme catalyzing dihydrotestosterone, in order to control the amount of dihydrotestosterone known to cause sebum secretion and acne production. The present invention was completed by finding that the striation among various natural products is particularly excellent in inhibiting effect of 5α-reductase, sebum secretion effect and acne relieving effect.
따라서, 본 발명의 목적은 능실 추출물을 유효성분으로 함유하는 5α-리덕테이즈 활성 억제용 조성물을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a composition for inhibiting 5α-reductase activity, which contains a twill extract as an active ingredient.
또한, 본 발명의 다른 목적은 능실 추출물을 유효성분으로 함유하는 피지 분비 억제용 또는 여드름 완화용 화장료 조성물을 제공하는데 있다.In addition, another object of the present invention to provide a cosmetic composition for inhibiting sebum secretion or acne relief containing the active ingredient extract as an active ingredient.
본 발명에 의해 제공되는 능실 추출물은 5α-리덕테이즈 저해효과가 우수할 뿐만 아니라, 이를 함유한 화장료 조성물을 피지의 과잉 분비 억제 효과 및 여드름 개선 효과가 우수하며, 피부에 자극이 거의 없었다. 따라서, 본 발명의 능실 추출물을 유효성분으로 함유하는 화장료 조성물은 제품에 영향을 미치지 않는 농도에서 피지 분비 억제 및 여드름 완화 효과가 있으므로 피지 분비 억제 화장료 또는 여드름 완화 화장료에 효과적으로 사용할 수 있다.The twill extract provided by the present invention not only has an excellent 5α-reductase inhibitory effect, but also a cosmetic composition containing the same, which has an excellent effect of inhibiting sebum oversecretion and improving acne, and hardly irritating the skin. Therefore, since the cosmetic composition containing the twill extract of the present invention as an active ingredient has sebum secretion suppression and acne relieving effect at a concentration that does not affect the product, it can be effectively used for sebum secretion inhibiting cosmetics or acne relief cosmetics.
본 발명에서 제공하는 5α-리덕테이즈 활성 억제용 조성물, 피지 분비 억제용 화장료 조성물 및 여드름 완화용 화장료 조성물은 능실을 유효성분으로 함유한다. The composition for inhibiting 5α-reductase activity, the cosmetic composition for inhibiting sebum secretion, and the acne-relieving cosmetic composition provided in the present invention contain the active ingredient as an active ingredient.
능실(Trapa japonica)은 쌍떡잎 식물로 이판화군 도금양목 마름과의 한해살이풀로서, 연못이나 소택지에서자라며 뿌리는 진흙 속에 박고 줄기가 길게 자라서 물 위에 뜬다. 잎은 뭉쳐난 것처럼 보이며 잎자루에 굵은 부분이 있는데 이는 공기 주머니로서 물 위에 뜰 수 있도록 해준다. 잎 몸은 마름모꼴 비슷한 삼각형이며 잔 톱니가 있다. 물 속 원줄기의 마디에서 깃 같은 뿌리가 내린다. Trapa japonica is a dicotyledonous plant, a yearly herbaceous plant with two-leaved plated cranberries, growing in ponds or marshes, roots in mud, long stems, and floating on water. The leaves appear to be clustered and have thick areas on the petioles, which allow them to float on the water as air pockets. The leaf body is a lozenge-like triangle with fine jagged teeth. Feather-like roots come from the nodes of the main stem in the water.
7~8월에 흰빛 또는 다소 붉은빛이 도는 꽃이 잎 겨드랑이에 피는데 지름 1cm정도로서 꽃잎은 4개이다. 화편은 짧고 위를 향하지만 열매가 커짐에 따라서 밑으로 굽으며 길이 2~4cm이다. 꽃받침잎은 털이 있고 수술은 4개, 암술은 1개이다. 열매는 딱딱하고 역삼각형이며 양 끝에 꽃받침조작이 변한 가시가 있고 중앙부가 두드러진다. A white or somewhat reddish flower blooms in the axilla in July-August, about 1cm in diameter, with 4 petals. Flowers are short and up, but bend downward as the fruit grows, 2 ~ 4cm long. The calyx leaves are hairy, with 4 stamens and 1 pistil. Fruits are hard, inverted triangular, with thorns with calyx change at both ends, with central part prominent.
종자는 1개씩 들어 있으며 식용한다. 민간에서는 열매를 해독제와 위암에 사용한다. 마름을 지나치게 먹으면 복부 창만 증세를 일으키는데, 생강즙을 술에 타 서 마시면 이를 방지할 수 있다. 마름의 잎은 어린아이의 afl가 헐었을 때, 과피는 이질, 설사, 탈항, 치질등에, 줄기는 위궤양을 치료할 때 쓰인다. 마름의 녹말은 구황식품으로도 이용된다. Seeds are contained one by one and eaten. In folklore, berries are used for antidote and stomach cancer. Eating too much dryness only causes abdominal swelling, and drinking ginger juice can help prevent this. The dry leaves are used when the afl of a child is broken down, the rind is used for dysentery, diarrhea, prolapse and hemorrhoids, and the stem is used to treat gastric ulcers. Dried starch is also used as a yellow wine.
마름은 잎꼭지가 두껍고 속이 비어 있어서 물위로 떠오르는 성질이 있어 물에 떠 자라는 한해살이풀로 항암작용이 있는 것으로도 일찍부터 알려졌다. 원래 이 열매는 한약명으로 능실, 수율이라고 하는데 예전에는 이것을 따서 찌거나 삶아서 먹고 죽을 끓여 먹는 등 식량으로 이용하기도 하였다. <약용식물사전>에 마름 열매를 달여 먹으면 두창을 낫게하고 술독을 풀며 눈을 밝게 할 뿐만 아니라 위암, 자궁암을 낫게 한다고 적혀 있으며 또 <약이 되는 식물>에 마름 열매 15-20개를 물로 달여서 하루 3번 나누어 마시면 갖가지 암에 효과가 있고 술독과 태독을 없애며 소화를 잘 되게 한다고 적혀있다.It is known to have anticancer activity as an annual herb that grows in water because its leaf stem is thick and hollow. Originally, this fruit is called medicinal herb and yield. In the past, it was steamed or boiled and eaten to boil porridge. The Medicinal Plant Dictionary says that if you eat dried fruit, it will not only heal the window, loosen the wine, brighten your eyes, but also cure stomach and uterine cancer. Drinking three times is effective in all kinds of cancer, eliminating alcohol poisoning and poisoning is said to be well digested.
중국에서 실험한 것에 따르면, 좀흰생쥐의 복수암과 간암에 마름 열매를 달인 물이 일정한 억제 작용을 나타냈고, 좀흰생쥐의 사르코마-180암에는 60%퍼센트의 억제 효과가 있었다고 한다. In China, experiments showed that water-sweetened water in the ascites and liver cancers of rats had a certain inhibitory effect, and that 60% percent of sarcoma-180 cancers in rats had a certain inhibitory effect.
마름 열매는 그 껍질에 항암활성이 있어 위암, 식도암, 자궁암에는 마름열매를 가루내어 물이나 꿀물과 함께 먹고, 또 갖가지 암에 마름열매, 율무, 번행초, 등나무 혹을 달여서 하루 3번에 나누어 먹으며 마름잎이나 줄기도 차로 달여 수시로 마시면 좋다고 한다.The dried fruit has anti-cancer activity on its bark, so the stomach, esophageal, and uterine cancers can be dried with powdered water or honey water, and the various kinds of cancers are dried with three pieces of dried fruit, yeolmu, burnt vines and wisteria lumps. The leaves and stems are also sweetened with tea, so it is good to drink from time to time.
일본에서 펴낸 <가정 간호의 비결>이란 책에는 마름 열매를 흙으로 만든 그릇에 넣어 약한 불로 오래 달여서 그 물을 하루 3~4번 복용하면, 병원에서 포기한 위암이나 자궁암 환자도 희망을 가질 수 있다고 적혀있다.The book The Secrets of Home Nursing in Japan states that dried fruit is placed in a bowl made of earth and dried on low heat for 3 to 4 times a day. have.
본 발명의 화장료 조성물에 있어서 능실 추출물은 능실 식물의 잎, 줄기, 뿌리, 꽃, 열매 등 다양한 기관으로부터 통상적인 방법으로 추출하여 얻은 것을 의미하고, 바람직하게는 열매, 줄기, 뿌리 및 잎으로부터 얻은 추출물을 의미한다.In the cosmetic composition of the present invention, the twill extract means that the extract is obtained by a conventional method from various organs such as leaves, stems, roots, flowers, and fruits of the twill plant, preferably an extract obtained from the fruits, stems, roots and leaves. Means.
본 발명의 능실 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건 하에서, 통상적인 용매를 사용하여 제조될 수 있다.The twill extract of the present invention may be prepared according to conventional methods known in the art, i.e., under the conditions of conventional temperature and pressure, using conventional solvents.
상기 능실 추출물은 다양한 추출 용매, 예를 들어, 물, 탄소수 1-4의 무수 또는 함수 저급 알코올 (메탄올, 에탄올, 프로판올 및 부탄올), 아세톤, 에틸 아세테이트, 클로로포름, 1,3-부틸렌글리콜 및 부틸 아세테이트로 구성된 군으로부터 선택되는 추출 용매로 하여 얻을 수 있으며, 바람직하게는 물과 에탄올의 적절한 혼합액을 이용하여 얻어진 것이고, 보다 바람직하게는 물과 에탄올이 3:7로 혼합된 혼합용액을 이용하여 얻어진 것이다. 한편, 본 발명의 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.The twill extract may be selected from a variety of extraction solvents, such as water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, propanol and butanol), acetone, ethyl acetate, chloroform, 1,3-butylene glycol and butyl It can be obtained as an extraction solvent selected from the group consisting of acetate, preferably obtained by using a suitable mixture of water and ethanol, more preferably obtained by using a mixed solution of 3: 7 mixed with water and ethanol will be. On the other hand, it will be apparent to those skilled in the art that the extract of the present invention can be obtained in addition to the above-described extraction solvents, extracts having substantially the same effect using other extraction solvents.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract by the above-described extraction solvent, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). The active fraction is also included in the extract of the present invention.
본 발명의 바람직한 구현예에 따르면, 상기 능실 추출물의 함량은 화장료 조성물의 총 중량에 대하여 0.0001~10중량%이며, 바람직하게는 0.5~5%이며, 가장 바람직하게는 1.0~3.0중량%이다.According to a preferred embodiment of the present invention, the content of the twill extract is 0.0001 to 10% by weight, preferably 0.5 to 5%, most preferably 1.0 to 3.0% by weight relative to the total weight of the cosmetic composition.
능실 추출물의 함량이 0.0001중량% 미만이면, 능실 추출물에 의한 효과를 기대할 수 없는 문제점이 있고, 10중량%를 초과하는 경우에는 함유량의 증가에 따른 뚜렷한 효과의 증가가 없고, 오히려 피부 자극을 초래할 수 있으며, 제형상의 안정성에 문제점이 있다.If the content of the twill extract is less than 0.0001% by weight, there is a problem that the effect by the twill extract can not be expected, and when the content of the twill extract exceeds 10% by weight, there is no apparent increase in effect due to the increase in content, but may cause skin irritation. And there is a problem in the stability of the formulation.
본 발명의 화장품 조성물에 포함되는 성분은 유효 성분으로서의 능실 추출물 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to the twill extract as an active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and Carrier.
본 발명의 화장료 조성물은 상기 성분 이외에도 필요에 따라 추가로 점증제, 피부보호제, 보습제, 중화제, pH 조절제, 가용화제, 방부제, 용제를 포함할 수 있다.The cosmetic composition of the present invention may further include a thickener, a skin protectant, a moisturizer, a neutralizer, a pH adjuster, a solubilizer, a preservative, and a solvent as needed in addition to the above components.
본 명세서에서 언급되는 "여드름"은 당업계에서 여드름 통칭되는 모든 피부 질환 또는 여드름과 유사한 기전을 통해 발명되는 모든 피부 질환을 포함한다. 예 컨대, 집합성 여드름, 브롬화물에 의한 여드름, 일반적 여드름, 응괴 여드름(congoblate acne), 화장품 사용에 의한 여드름, 디터지칸 여드름(acne dtergicans), 청춘기 여드름, 섬광모양의 여드름(acne fulminans), 절성 여드름(acne furunculoid), 할로겐에 의한 여드름, 경결성 여드름, 켈로이드성 여드름, 물리적 자극에 의한 여드름(mechanical acne), 약물성 여드름, 괴사성 여드름, 속립성 여드름, 신생아 여드름(acne neonatorum), 지성 여드름(acne oil), 구진성 여드름, 적창(pomade acne), 월경전 여드름, 주사 여드름(acne rosacea), 모창성 여드름, 열대성 여드름(tropical acne), 중독성 여드름(acne venenata), 및 심상성 여드름 등을 포함한다.As used herein, "acne" includes any skin disease known in the art as acne or any skin disease invented through a mechanism similar to acne. Examples include, collective acne, bromide acne, common acne, congoblate acne, acne from cosmetic use, acne dtergicans, adolescent acne, acne fulminans, and aging Acne furunculoid, acne caused by halogen, acne acne, keloid acne, mechanical acne, drug acne, necrotic acne, lip acne, neonatal acne neonatorum, oily acne (acne oil), papular acne, pomade acne, premenstrual acne, acne rosacea, swelling acne, tropical acne, acne venenata, and vulgar acne. Include.
본 발명의 피지 분비 감소 또는 여드름 개선용 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더 비누, 계면활성제-함유 클린싱, 오일, 분말, 파운데이션, 유탁액과 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징크림, 클렌징포옴, 클렌징워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The sebum secretion reducing or acne improving composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powder soaps, Surfactant-containing cleansing, oils, powders, foundations, emulsions and foundations, wax foundations, sprays, and the like, but are not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethyleneglycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
이하, 제조예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Experimental Examples. These examples are only for illustrating the present invention in more detail, it is to those of ordinary skill in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. Will be self-evident.
제조예1 : 능실 추출물의 제조Preparation Example 1 Preparation of Twill Extract
곱게 자른 능실의 열매, 줄기, 뿌리 및 잎을 1kg을 에틸알코올과 물이 7:3(v/v)으로 혼합된 수용액에 5일 동안 침지시키고, 300메쉬의 여과막을 통하여 여과한 다음, 진공 감압 농축기를 이용하여 80℃에서 농축시켰다. 이렇게 하여 얻어진 능실 파우더는 하기 실험예 또는 제품에 적용하기 용이하게 1,3-부틸렌 글리콜에 용해시켜 사용하였다.1 kg of finely cut twill fruit, stem, root and leaf were immersed in an aqueous solution mixed with ethyl alcohol and water at 7: 3 (v / v) for 5 days, filtered through a 300 mesh filtration membrane, and then vacuum reduced. Concentrated at 80 ° C. using a concentrator. The twill powder thus obtained was used after being dissolved in 1,3-butylene glycol to be easily applied to the following experimental examples or products.
실험예 1. 능실 추출물의 5α-리덕테이즈 활성 저해 효과 시험Experimental Example 1. 5α-Reductase activity inhibitory effect test
능실 추출물이 5α-리덕테이즈의 활성을 저해하는 억제제인지를 확인하고자 본 실험을 실시하였다. This experiment was carried out to determine whether the extract of the twill is an inhibitor that inhibits the activity of 5α-reductase.
1-1. 효소액의 제조1-1. Preparation of Enzyme Liquid
24시간 절식한 성숙한 스트레그 돌리 랫드(Sprogue-Dawley rat)(생후 7~8주)을 디에틸이서로 치사시키고 나서, 간장을 빙냉한 크랩스-링거 포스페이트 완충액(Krebs-Ringer phosphate buffer)(pH 7.2)로 관류하였다. 여기에 5배량의 빙냉한 트리스 에이치시엘 완충액(Tri-HCL buffer, pH7.2)를 가하여 호모게나이즈하고, 900Xg, 10분간 원심 분리하였다. 상층을 5000Xg, 10분간 원심분리하고, 그 상층을 9000Xg, 10분간 원심분리할 때 얻은 상층을 효소액으로 사용했다. 효소액은 80℃에서 동결보존하였다.A 24-hour fasted Sprogue-Dawley rat (7-8 weeks old) was killed with diethyl ether, and the liver was ice-cold in Crebs-Ringer phosphate buffer (pH). Perfusion). Five times of ice-cold Tris HSI buffer (Pri-HCL buffer, pH 7.2) was added thereto and homogenized, followed by centrifugation at 900Xg for 10 minutes. The upper layer was centrifuged at 5000Xg for 10 minutes, and the upper layer obtained when the upper layer was centrifuged at 9000Xg for 10 minutes was used as the enzyme solution. The enzyme solution was cryopreserved at 80 ° C.
1-2. 5α-리덕테이즈의 저해 효과 시험1-2. Inhibitory effect test of 5α-reductase
트리스 에이치시엘 완충액(Tris-Hcl buffer, pH 7.2) 1.0ml에 테스토스테론 (500ug/ml) 0.3ml, 제조예 1에서 준비된 능실추출물을 0.1, 0.2, 0.5, 1%의 농도로 0.2ml을 및 효소액 1.0ml을 혼화하고, NADPH (0.77mg/ml) 0.5ml을 가하여 반응을 개시하고, 37℃ 에서 30분간 반응시켰다. 디클로로메탄(Dichloromethane) 5ml을 가하여 반응을 정지시켜, 내부 표준물질(p-hydroxybenzoic acid n-hexyl ester, 0.1mg/ml) 0.5ml을 가하여 10분간 진탕하고, 3000rpm에서 10분간 원심분리하였다. 상층을 제거한 후, 디클로로메탄층을 남기고, 여기에 메탄올(methanol) 5ml을 가하여 고속 액체크로마토그래피(HPLC)용 시료로 하였다.0.3 ml of testosterone (500 ug / ml) in 1.0 ml of Tris-Hcl buffer (pH 7.2), twill extract prepared in Preparation Example 1 at a concentration of 0.1, 0.2, 0.5, 1%, and enzyme solution 1.0 The ml was mixed, 0.5 ml of NADPH (0.77 mg / ml) was added to initiate the reaction, and the reaction was carried out at 37 ° C for 30 minutes. 5 ml of dichloromethane was added to stop the reaction. 0.5 ml of an internal standard (p-hydroxybenzoic acid n-hexyl ester, 0.1 mg / ml) was added thereto, shaken for 10 minutes, and centrifuged at 3000 rpm for 10 minutes. After the upper layer was removed, a dichloromethane layer was left, and 5 ml of methanol was added thereto to prepare a sample for high performance liquid chromatography (HPLC).
5α-리덕테이즈 저해율은 HPLC 방법을 이용하여 각 실험군의 테스토스테론의 양을 측정한 뒤 하기 수학식 1의 계산식에 따라 산출하였으며, 그 결과를 표 1에 나타내었다.5α-reductase inhibition rate was calculated according to the following formula 1 after measuring the amount of testosterone of each experimental group using the HPLC method, the results are shown in Table 1.
* cont 0 : 능실 추출물을 가하지 않고, NADPH를 가하기 전에 디클로로메탄을 가해서 반응을 일으키지 않도록 한 것* cont 0: without adding succinct extract and adding dichloromethane before adding NADPH to avoid reaction
* cont 1 : 능실 추출물을 가하지 않고 수행한 것* cont 1: done without addition of the intact extract
표 1의 결과에서 알 수 있듯이, 능실 추출물은 5α-리덕테이즈의 활성을 약 0.1%농도에서 93.5%로 억제하여, 처리농도 의존적으로 5α-리덕테이즈의 활성을 억제함을 확인 할 수 있었다. 그러므로, 5α-리덕테이즈 활성을 억제하는 능실 추출물은 남성 호르몬 디하이드로스테론의 생성량을 억제하는 효과가 있음을 알 수 있었다.As can be seen from the results of Table 1, it was confirmed that the twill extract inhibited the activity of 5α-reductase from about 0.1% to 93.5%, thereby inhibiting the activity of 5α-reductase depending on the treatment concentration. . Therefore, it was found that the stalk extract that inhibits 5α-reductase activity has an effect of suppressing the amount of testosterone dihydrosterone produced.
실험예 2. 면포 억제 시험Experimental Example 2
토끼의 귀에 면포 유발물질을 처리하면 1주일 경과 후부터는 면포가 커지는데 일반적으로 면포가 커지는 것은 여드름의 염증이 일어나기 전단계와 같은 양상이다. 면포가 커지면서 모공 내에는 피지가 과량 들어 있게 되고 이로 인해 모공도 정상적인 상태보다 커지게 된다. 따라서, 면포 발생 실험은 사람에서의 여드름 효과와는 다소 다르지만 현재로서 가장 여드름과 유사한 양상을 보이는 실험 모델이다. Treating a cotton-causing agent in the rabbit's ears will cause the cotton to grow after one week, but the larger cotton usually looks the same as before acne's inflammation. As the scalp grows, there is an excess of sebum in the pores, which causes the pores to become larger than normal. Thus, the scum outbreak experiment is somewhat different from the acne effect in humans, but it is the experimental model that is most similar to acne at present.
제조예 1에서 준비된 능실 추출물이 면포 억제 능력이 있는지 확인하고자 아래와 같은 실험을 실시하였다. In order to check whether the twill extract prepared in Preparation Example 1 has a scrim suppression ability, the following experiment was performed.
흰토끼의 귀에 면포 유발 물질인 50% 올레익산/파라핀 오일을 200ul씩 하루 1번 도포하여 면포를 유발시킴과 동시에, 제조예 1에서 준비된 능실 추출물을 화장품 원료이며 면포를 유발하지 않는 1,3-BG에 1%로 녹여, 하루에 2번 200ul씩 도포하였다. 대조군으로 올레익산을 처리하고 능실 추출물을 바르지 않은 군(대조군)으로 설정하여 실험하였다. 면포의 수는 면포의 크기가 0.2mm 이상되는 것을 기준으로 삼았다. 면포 발생 부위의 조직을 0.8mm절편하여 각질을 벗겨낸 후, 광학현미경으로 면포의 크기를 측정하였다. A~E는 면포의 크기를 측정하기 위해 절편 한 조직에서 전체 면포들 중 면포가 잘 발달된 것들 중에서 무작위로 6개를 선정해 면포 크기를 측정하였으며, 그 결과를 표 2에 나타내었다.Applying 200ul of 50% oleic acid / paraffin oil, which is a cotton-causing substance, to the rabbit's ears once a day to induce cotton cloth, and simultaneously extract the twill extract prepared in Preparation Example 1 as a cosmetic raw material and not causing cotton cloth. Dissolved in 1% in BG, 200ul was applied twice a day. Experiments were performed by treating oleic acid as a control group and setting the group without applying the twill extract (control). The number of cotton cloth was based on the size of the cotton cloth being 0.2 mm or more. After exfoliation of the tissue of the scleroderma site by 0.8 mm, the size of the scrim was measured by an optical microscope. In order to measure the size of the cotton wool, A ~ E randomly selected six among the well-developed ones from the whole tissue and measured the size of the cotton cloth. The results are shown in Table 2.
상기 표 2의 결과에서도 알 수 있듯이, 본 발명의 능실 추출물이 올레익산 처리에 따른 면포의 발생을 효과적으로 억제하였다. 즉 능실 추출물의 처리에 의해 면포의 수와 크기가 적게 발생하는 결과를 통해 능실 추출물이 피지의 분비를 적게 유발시키고 여드름으로의 진행을 억제하는 것임을 예측할 수 있었다.As can be seen from the results of Table 2, the extract of the present invention effectively suppressed the generation of cotton cloth according to the oleic acid treatment. In other words, the treatment resulted in the small number and size of cotton cloths treated by the twill extract, suggesting that the twill extract induced less sebum secretion and inhibited the progression to acne.
상기 실험을 통해 능실 추출물이 피지 분비의 원인이 되는 5α-리덕테이즈의 활성을 저해하여 피지 분비를 억제함으로써 면포의 발생을 효과적으로 억제하여 여드름을 완화시킬 수 있음을 간접적으로 확인하였다. 이에, 능실 추출물이 피지 분비 억제 및 여드름 완화 효과를 갖는지 직접적으로 확인하기 위해 이하 아래의 제형예를 통하여 능실 추출물을 함유하는 화장료의 제형예를 제시하나 모든 처방이 이에 한정되는 것은 아니다.Through the above experiments, it was indirectly confirmed that the twill extract inhibited the activity of 5α-reductase causing sebum secretion, thereby inhibiting sebum secretion, thereby effectively suppressing the occurrence of cotton blemishes and alleviating acne. Thus, in order to directly confirm whether the extract of the twill extract has sebum secretion and acne relieving effect, the following formulation example shows a formulation example of a cosmetic containing a twill extract, but not all prescriptions are limited thereto.
제형예 1. 유연 화장수 Formulation Example 1 Flexible Lotion
제조예 1의 능실 추출물을 함유한 화장료 중 유연 화장수의 제형예는 다음과 같다. 또한 비교를 위해서 능실 추출물을 함유하지 않은 비교실시예1 및 피지분비 억제 효능을 갖는다고 알려진 백굴채(Chelidonium majus) 추출물 (대한민국특허등록 제702329호)을 함유하는 비교실시예2를 함께 제형예로 제조하였다. Formulation examples of the flexible lotion in the cosmetic containing the twill extract of Preparation Example 1 are as follows. Also for comparison, Comparative Example 1 containing no twill extract and Comparative Example 2 containing Chelidonium majus extract (Korean Patent Registration No. 720329), which are known to have sebum secretion efficacy, were used as a formulation example. Prepared.
제형예 2. 수렴 화장수Formulation Example 2. Convergence Lotion
제조예 1의 능실 추출물을 함유한 화장료 중 수렴 화장수의 제형예는 다음과 같다.Formulation examples of the astringent lotion in the cosmetic containing the twill extract of Preparation Example 1 are as follows.
제형예 3. 영양 화장수Formulation Example 3 Nutritional Lotion
제조예 1의 능실 추출물을 함유한 화장료 중 영양 화장수의 제형예는 다음과 같다.The formulation example of the nutritional lotion in the cosmetic containing the twill extract of Preparation Example 1 is as follows.
제형예 4. 영양 크림Formulation Example 4. Nutrition Cream
제조예 1의 능실 추출물을 함유한 화장료 중 영양 크림의 제형예는 다음과 같다.Formulation example of the nutrient cream in the cosmetic containing the twill extract of Preparation Example 1 is as follows.
제형예 5. 맛사지 크림Formulation Example 5. Massage Cream
제조예 1의 능실 추출물을 함유한 화장료 중 맛사지 크림의 제형예는 다음과 같다.Formulation example of the massage cream in the cosmetic containing the twill extract of Preparation Example 1 is as follows.
제형예 6. 팩Formulation Example 6 Pack
제조예 1의 능실 추출물을 함유한 화장료 중 팩의 제형예는 다음과 같다.Formulation examples of the pack in the cosmetic containing the twill extract of Preparation Example 1 are as follows.
제형예 7. 에센스Formulation Example 7 Essence
제조예 1의 능실 추출물을 함유한 화장료 중 에센스의 제형예는 다음과 같다.Formulation examples of the essence in the cosmetic containing the twill extract of Preparation Example 1 are as follows.
실험예 3. 피지 분비 억제 효과Experimental Example 3. Sebum secretion inhibitory effect
본 발명의 능실 추출물을 함유하는 화장료의 피지 분비 억제 효과가 있는지를 확인하기 위해 피지 분비량이 많은 20대 남녀 30명을 대상으로 A, B 및 C의 세 그룹으로 나누어 아래와 같은 실험을 실시하였다.In order to determine whether the sebum secretion inhibitory effect of the cosmetic containing the extract of the present invention is sebum secretion in the 20s men and women with a large amount of sebum secretion was divided into three groups of A, B and C as follows.
실험은 제형예 1에서 제조한 실시예 1 및 비교실시예 1, 2의의 제형을 이용하여 실험하였으며, A 그룹에는 능실 추출물이 함유된 실시예 1의 유연 화장수를, B 그룹에는 능실 추출물이 함유되지 않은 비교실시예1을, C 그룹에는 피지분비억제효과가 있다고 알려져 있는 백굴채 추출물이 함유된 비교실시예 2를 매일 아침, 저녁 세안 후 4주간 사용하도록 하였다. 피지 측정은 세안 후 30분간 항온, 항습실에서 안정시킨 후 피지측정기(Sebumeter)를 이용하여, 이마에서 피지량을 측정하였다. 시험을 위한 유연 화장수를 사용하기 전 피지량을 초기값으로 설정하였으며, 해당 유연 화장수를 지속적으로 사용하면서 매주 1회 4주간 피지량의 변화를 측정하였다. 본 발명의 능실 추출물에 의한 피지량의 변화는 초기 피지량과 비교하여 피지 억제 효능 여부를 판정하였으며, 그 결과는 표 10에 나타내었다.The experiment was carried out using the formulations of Example 1 and Comparative Examples 1 and 2 prepared in Formulation Example 1, the flexible lotion of Example 1 containing the twill extract in Group A, and the twill extract was not included in Group B. In Comparative Example 1, group C, Comparative Example 2, which contains the extract of Sesame Seeds, known to have sebum secretion effect, was used every morning and evening for 4 weeks. Sebum measurement was stabilized in a constant temperature and humidity room for 30 minutes after washing the face, and then sebum was measured on the forehead by using a sebumeter. The sebum amount was set to an initial value before using the flexible lotion for the test, and the change in sebum amount was measured once a week for 4 weeks while using the flexible lotion continuously. The change of sebum amount by the extract of the present invention was determined whether the sebum inhibitory effect compared to the initial sebum amount, the results are shown in Table 10.
상기 표 10의 결과에서도 알 수 있듯이, 본 발명의 능실 추출물을 함유한 실시예 1의 유연 화장수는 아무것도 함유하지 않은 비교실시예 1과 비교하였을 때 시간이 지남에 따라 피지 분비를 효과적으로 감소시켰으며, 피지 분비 억제 효과를 가진다고 알려진 백굴채 추출물이 함유된 비교실시예 2와 비교하였을 때 피지분비효과에 있어 유사한 결과를 나타내는 것을 확인 할 수 있었다. 따라서, 본 발명의 능실 추출물은 피지 분비를 효과적으로 감소시킴으로써 피지의 과잉 분비로 인해 여드름이 발생하는 것을 방지할 수 있을 것으로 예측되어진다.As can be seen from the results of Table 10, the flexible lotion of Example 1 containing the twill extract of the present invention effectively reduced sebum secretion over time compared to Comparative Example 1 containing nothing, When compared with Comparative Example 2 containing the white bran extract known to have a sebum secretion inhibitory effect was confirmed to show a similar result in the sebum secretion effect. Therefore, it is expected that the twill extract of the present invention can effectively prevent sebum secretion from occurring due to excessive secretion of sebum by effectively reducing sebum secretion.
실험예 4 : 여드름 개선 효과Experimental Example 4: Acne Improvement
여드름이 발생한 남녀 10명으로 대상으로 실시예 1의 유연 화장수를 아침, 저녁으로 4주간 얼굴 전체에 고루 바르도록 하였다. 효과의 판정은 시험에 참가한 본인이 느끼는 정도에 따라 1~3점으로 평가하도록 하였다. Ten men and women with acne were subject to apply the flexible lotion of Example 1 evenly throughout the face for 4 weeks in the morning and evening. The effect was judged by 1 to 3 points depending on the degree of feeling felt by the person who participated in the test.
<시험전 상태의 평가><Evaluation before the test>
1 = 여드름 조금 있음 2 = 여드름 약간 있음 3 = 여드름 심함1 = some acne 2 = some acne 3 = severe acne
<여드름 효과 판정><Acne effect judgment>
- : 효과 거의 없음 + : 약간의 효과 있음-: Almost no effect +: Slight effect
++ : 많이 완화 +++ : 완전히 치유됨++: Relaxed a lot +++: Completely healed
상기의 표 11의 결과에서도 알 수 있듯이, 본 발명의 능실 추출물이 함유된 실시예 1의 유연 화장수를 4주간 사용한 결과, 대다수의 피험자들에서 여드름 개선 효과를 확인할 수 있었다.As can be seen from the results of Table 11 above, as a result of using the flexible lotion of Example 1 containing the twill extract of the present invention for 4 weeks, the majority of subjects were able to confirm the improvement of acne.
실험예 5. 능실 추출물의 안전성 평가Experimental Example 5. Evaluation of Safety of Twill Extract
본 발명의 능실 추출물이 함유된 화장료의 안정성을 평가하기 위하여 다음과 같이 스팅 테스트(Stinging test)을 실시하였다. 테스트는 25세-33세의 피검자 15명을 대상으로 시험하였으며, 평균연령은 31.5세였다. 스팀 발생기(Steam generator)를 사용하여 15분간 충분히 발한시키고 나서, 충분량의 시료를 손에 묻혀 제형예 4에서 제조한 영양크림인 실시예 2 및 비교실시예 3을 각각 왼쪽과 오른쪽의 코 주위 및 뺨을 중심으로 강하게 비빈다. 반응정도는 영양크림 적용 후 자극 반응이 나타나는 시간에 따라 30초 이내에 나타나는 경우를 강자극 (Severe Irritation), 2.5분 이내에 나타나는 경우를 중자극 (Strong Irritation), 5분 이내에 나타나는 경우를 미자극 (Moderate Irritation)및 8분 이내에 나타나는 경우를 무자극 (No irritation)으로 분류하여 평가하였으며, 백분율로 환산한 반응률(%) 및 판정 결과를 표 12에 나타내었다.In order to evaluate the stability of the cosmetic containing the twill extract of the present invention, the Sting test was performed as follows. The test was conducted on 15 subjects aged 25-33 years with an average age of 31.5 years. After a sufficient period of sweating for 15 minutes using a steam generator, a sufficient amount of the sample was buried in the hands, and Example 2 and Comparative Example 3, which were the nutrition creams prepared in Formulation Example 4, were placed around the nose and cheeks on the left and right sides, respectively. Rubbing strongly around. The degree of response was found to be within 30 seconds depending on the time of stimulation response after applying nourishing cream.Severe Irritation; within 2.5 minutes; Strong Irritation; within 5 minutes. Irritation) and cases appearing within 8 minutes were evaluated as classified as no irritation, and the reaction rate (%) and the determination result in terms of percentage are shown in Table 12.
상기 표 13의 결과에서도 알 수 있듯이, 본 발명의 능실 추출물을 함유하는 화장료 조성물은 피부 자극이 극히 미약함을 확인할 수 있었다.As can be seen from the results of Table 13, the cosmetic composition containing the extract of the present invention was found to be extremely weak skin irritation.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070110408A KR100927970B1 (en) | 2007-10-31 | 2007-10-31 | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070110408A KR100927970B1 (en) | 2007-10-31 | 2007-10-31 | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090044339A KR20090044339A (en) | 2009-05-07 |
KR100927970B1 true KR100927970B1 (en) | 2009-11-24 |
Family
ID=40854910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070110408A Active KR100927970B1 (en) | 2007-10-31 | 2007-10-31 | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100927970B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015141926A1 (en) * | 2014-03-17 | 2015-09-24 | 코스맥스 주식회사 | Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient |
KR20210034207A (en) | 2019-09-20 | 2021-03-30 | 서승옥 | Cosmetic composition containing Trapa japonica Flerov callus extracts |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020050411A (en) * | 2000-12-21 | 2002-06-27 | 성재갑 | The compositions inhibiting 5 alpha-reductase activity |
KR20050108746A (en) * | 2004-05-13 | 2005-11-17 | 학교법인 인제학원 | Composition comprising an extract of trapa japonica flerov. showing antioxidative effect |
KR20060116896A (en) * | 2005-05-11 | 2006-11-16 | 학교법인 인제학원 | Composition for improvement of lipid metabolism and prevention and treatment of complications due to diabetes including dried extract |
-
2007
- 2007-10-31 KR KR1020070110408A patent/KR100927970B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020050411A (en) * | 2000-12-21 | 2002-06-27 | 성재갑 | The compositions inhibiting 5 alpha-reductase activity |
KR20050108746A (en) * | 2004-05-13 | 2005-11-17 | 학교법인 인제학원 | Composition comprising an extract of trapa japonica flerov. showing antioxidative effect |
KR20060116896A (en) * | 2005-05-11 | 2006-11-16 | 학교법인 인제학원 | Composition for improvement of lipid metabolism and prevention and treatment of complications due to diabetes including dried extract |
Non-Patent Citations (1)
Title |
---|
"Trapanins A and B, Oligomeric Hydrolyzable Tannins from Trapa japonica Flerove" HTATNO, TSUTOMU, et al., Chem. Pharm. Bull. 38(10), 2707-2711, 1990 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015141926A1 (en) * | 2014-03-17 | 2015-09-24 | 코스맥스 주식회사 | Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient |
KR20210034207A (en) | 2019-09-20 | 2021-03-30 | 서승옥 | Cosmetic composition containing Trapa japonica Flerov callus extracts |
Also Published As
Publication number | Publication date |
---|---|
KR20090044339A (en) | 2009-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3529811B2 (en) | External preparation for skin | |
KR101146206B1 (en) | Cosmetic Composition And Composition of Skin External Application | |
KR101393007B1 (en) | Cosmetic Composition for Skin-aging Protection and Wrinkle Improvement Comprising the Extract of Nephelium lappaceum and Litchi chinensis sonn as Active Ingredient | |
CN105555285B (en) | For promoting the composition of hair tonic and hair growth | |
KR101595530B1 (en) | Liposome composition having excellent effect of skin wrinkle improvement and skin whitening for accelerating percutaneous absorption | |
KR101350292B1 (en) | Cosmetic composition containing fermented extracts of panax ginseng root, ganoderma lucidum and white tea and method for preparing the same | |
KR100443588B1 (en) | Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect | |
KR20200063612A (en) | Cosmetic Composition containing Bottle Gourd Extract and Manufacturing method of thereof | |
KR101473940B1 (en) | Hair cosmetic composition for preventing hair loss and improving the scalp comprising the complex extracts of Swertia japonica MAKINO, Paeonia lactiflora, quisetum arvense L. and peach | |
KR20100089409A (en) | Cosmetic composition for acne improvement | |
KR20140145278A (en) | Cosmetic composition containing Cimicifuga heracleifolia extract, Cornus officinalis extract and Geranium nepalense extract for skin convergence and elasticity effect | |
KR100858627B1 (en) | Sebum secretion cosmetic composition containing the extract as an active ingredient | |
KR20090032583A (en) | Yang yang extract inhibiting the activity of 5α-reductase and sebum secretion inhibiting or acne improving cosmetic composition containing the same | |
KR101542490B1 (en) | Cosmetic composition comprising the mixed extracts of Achillea, Borage, Helichrysum, Lady's mantle, and Eucalyptus | |
KR102335683B1 (en) | Cosmetic composition for alleviating acne comprising rosa rugosa extract and salvia plebeia extract | |
KR100927970B1 (en) | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition | |
KR20100030432A (en) | Cosmetic composition for skin moisturizing comprising the seven flowers extract as active ingredient | |
KR101252550B1 (en) | Cosmetic composition for protecting sebum secretion on the skin | |
KR100977673B1 (en) | Cosmetic composition for promoting blood circulation and improving skin color containing a complex of plant extracts (Chillbaek Jingo extract) | |
KR100754748B1 (en) | 5α-reductase activity inhibiting composition and sebum secretion inhibiting cosmetic composition containing elm extract as an active ingredient | |
KR102208482B1 (en) | Cosmetic composition for improving skin troubles | |
KR20160068303A (en) | Cosmetic composition for improving skin dryness, trouble or edema by hangover | |
KR20190133085A (en) | A composition and Manufacturing method for preventing hair loss and promoting hair growth, the composition comprising Rheum undulatum Linne extract and Chinese Hawthorn extract as main components | |
KR20110022131A (en) | Sebum secretion cosmetic composition comprising the extract | |
KR20210059517A (en) | Quadruple complex and the composition ratio using Moringa Oleifera Oil, Vitellaria Nilotica (Shea) Butter, Centella Asiatica Extract, Glycyrrhiza Uralensis Extract for maximizing atopic dermatitis improvement and preventive efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20071031 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090223 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20090917 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20091116 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20091116 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20120928 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20120928 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131021 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20131021 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160927 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20160927 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20180918 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191119 Year of fee payment: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20191119 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20200925 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20221011 Start annual number: 14 End annual number: 14 |
|
PR1001 | Payment of annual fee |